Skip to main content

Table 2 High-dose chemotherapy/ASCT

From: Low-dose peripheral blood stem cell graft after high-dose chemotherapy - an evaluation of hematopoietic reconstitution

Parameter

Overall cohort

Group 1 (3–4 × 106 CD34+ cells /kg bw)

Group 2 (2–2.5 × 106 CD34+ cells /kg bw)

P value Group 1 vs. 2

Group 3 (< 2 × 106 CD34+ cells /kg bw)

ASCTs analyzed, n

148

86

53

/

9

Sequential ABSCTs, n (%)

   

/

 

 First

142 (96)

86 (100)

53 (100)

3 (33)

 Second

5 (3)

0 (0)

0 (0)

5 (56)

 Third

1 (1)

0 (0)

0 (0)

1 (11)

Remission pre ABSCT, n (%)

   

0.168a

 

 CR

2 (1)

2 (2)

0 (0)

0 (0)

 nCR

38 (26)

28 (33)

9 (17)

1 (11)

 VGPR

48 (32)

26 (30)

21 (40)

1 (11)

 PR

45 (30)

21 (24)

18 (34)

6 (67)

 MR

4 (3)

3 (3)

1 (2)

0 (0)

 SD

1 (1)

0 (0)

1 (2)

0 (0)

 PD

6 (4)

2 (2)

3 (6)

1 (11)

 NA

4 (3)

4 (5)

0 (0)

0 (0)

Median age at ASCT, years (range)

61 (41–75)

61 (44–73)

62 (41–72)

0.886

60 (50–75)

Transplanted PBSCs

 Median transplanted CD34+ cells ×106/kg (range)

3.2 (1.7–4.0)

3.6 (3.0–4.0)

2.3 (2.0–2.5)

< 0.001

1.9 (1.7–1.99)

 Median vitality, % (range)

79 (53–93)

76 (53–93)

81 (58–93)

0.012

80 (66–93)

HD chemotherapy, n (%)

   

/

 

 Melphalan 2 × 100 mg/m2

146 (99)

85 (99)

53 (100)

8 (89)

 Dose reduction

2 (1)

1 (1)

0 (0)

1 (11)

Remission post ASCT, n (%)

   

0.316b

 

 CR

15 (10)

11 (13)

4 (8)

0 (0)

 nCR

42 (28)

30 (35)

11 (21)

1 (11)

 VGPR

54 (36)

27 (31)

22 (42)

5 (56)

 PR

25 (17)

11 (13)

12 (23)

2 (22)

 MR

5 (3)

3 (3)

2 (4)

0 (0)

 SD

1 (1)

1 (1)

0 (0)

0 (0)

 PD

2 (1)

2 (2)

0 (0)

0 (0)

 NA

4 (3)

1 (1)

2 (4)

1 (11)

  1. a/bCR/nCR/VGPR versus PR/MR/SD/PD.
  2. ASCT autologous blood stem cell transplantation; CR complete remission; HD high-dose; MR minimal response; NA not available; nCR near complete remission; PD progressive disease; PR partial remission; SD stable disease; VGPR very good partial remission; vs., versus